Over the past decade, the introduction of
|
|
- Alexandra Jones
- 5 years ago
- Views:
Transcription
1 MANAGEMENT OF CHRONIC HEPATITIS C IN HIV-INFECTED PATIENTS: CLINICAL EXPERIENCE WITH PEGYLATED INTERFERON α PLUS RIBAVIRIN Raymond T. Chung, MD* ABSTRACT Coinfection with hepatitis C virus (HCV) is common among persons infected with the human immunodeficiency virus (HIV). Treatment regimens based on standard interferon α (IFN α) and ribavirin (RBV) are recommended for chronic HCV, but they pose special concerns in patients coinfected with HIV, particularly those patients who are receiving antiretroviral therapy. Recently, several randomized studies comparing the safety and efficacy of pegylated interferon α (PEG-IFN α) plus RBV to IFN α plus RBV for the treatment of HCV in HIV-coinfected patients have been completed. In the AIDS Clinical Trials Group A5071 and RIBAVIC (sponsored by the French National Research Group) trials, superior sustained virologic responses were obtained with PEG-IFN α plus RBV compared to IFN α plus RBV. Findings from these studies suggest that PEG-IFN α plus RBV regimens may provide clinical benefit even in the absence of virologic clearance. An overview of these studies is presented. (Adv Stud Med. 2005;5(4C):S366-S370) *Assistant Professor of Medicine, Harvard Medical School, Director of Hepatology, Medical Director, Liver Transplant Program, Massachusetts General Hospital, Boston, Massachusetts. Address correspondence to: Raymond T. Chung, MD, Assistant Professor of Medicine, Harvard Medical School, Director of Hepatology, Medical Director, Liver Transplant Program, Massachusetts General Hospital, Blake 4, 55 Fruit Street, Boston, MA rtchung@partners.org. Over the past decade, the introduction of highly active antiretroviral therapy (HAART) for the treatment of human immunodeficiency virus (HIV) has shifted the spectrum of disease morbidity and mortality in these patients. Liver disease associated with chronic hepatitis C virus (HCV) and drug-induced hepatotoxicity has emerged as one of the most complex and important determinants of health in patients with HIV infection and AIDS. 1,2 Experience in treating HCV infection in patients with HIV has been largely dictated by experience in treating patients infected with only HCV. 3,4 The current standard of care for chronic infection with HCV in patients with no other infections is pegylated interferon α (PEG-IFN α)-2a or -2b plus ribavirin (RBV). 5 This combination of PEG-IFN α plus RBV produces sustained virologic response (SVR) rates of 54% to 63% in patients with HCV alone. 6-8 Given the importance of treating HCV infection in patients coinfected with HIV, the efficacy of this combination in the setting of HIV coinfection has recently been evaluated in several randomized clinical trials Findings from these trials indicate that PEG- IFN α plus RBV is well tolerated and provides superior rates of SVR when compared to interferon (IFN) α plus RBV regimens in patients infected with HIV and HCV. Furthermore, PEG-IFN α plus RBV may provide clinical benefits even in the absence of virologic clearance. This article reviews the rationale and special considerations for the use of PEG-IFN α plus RBV therapy. Results from 2 recently completed large randomized trials are highlighted in this overview: the AIDS Clinical Trials Group (ACTG) A5071 (PEG- IFN α-2a plus RBV) and the French RIBAVIC (PEG- IFN α-2b plus RBV), both comparing PEG-IFN α plus RBV to IFN α plus RBV. S366 Vol. 5 (4C) April 2005
2 HEPATITIS C VIRUS THERAPY IN PATIENTS WITH HIV One of the goals of HCV treatment is viral eradication. In early studies, Soriano et al found that viral eradication can be achieved with IFN-α treatment in patients coinfected with HIV/HCV. 14,15 However, higher titers of HCV RNA in HIV-coinfected patients, along with qualitative and quantitative alterations in immune function, may make this goal difficult to achieve. Therefore, improvement in or delayed progression of fibrosis may be a more realistic goal for most coinfected patients. Additional benefits of HCV treatment in patients with HIV may include improved tolerability and effectiveness of HAART. 16 Despite the potential benefits of HCV treatment, there are several issues to be considered when using anti-hcv therapy in patients coinfected with HIV/HCV. Common side effects of IFN α include influenza-like symptoms, depression, thrombocytopenia, and neutropenia. RBV therapy is also associated with dose-dependent hemolytic anemia, birth defects, and drug interactions with antiretroviral agents. Hematologic side effects, most notably anemia, may be particularly severe in coinfected patients because of a high prevalence of anemia and limited erythroid reserves that may be associated with comorbid disease or concurrent antiretroviral-induced myelosuppression. Although anemia can be managed by reducing the RBV dose, this may have an undesired effect of reducing SVR rates. The use of erythropoietin, which can counteract RBV-related anemia, may therefore be an important adjunct to therapy in coinfected persons. 17 In addition, drug interactions between RBV and certain antiretroviral agents could result in decreased efficacy and increased toxicity of these agents. RBV antagonizes the in vitro anti-hiv activity of the thymidine analogues zidovudine and stavudine by inhibiting intracellular phosphorylation needed for their antiviral activity. 18 Fortunately, this interaction does not appear to be observed in vivo. However, RBV also enhances formation of the active metabolite of didanosine (ddi), resulting in increased activity and, particularly, increased risk of mitochondrial toxicity in patients receiving this nucleoside analogue. Finally, RBV may also increase the risk of other nucleoside reverse transcriptase inhibitor-related mitochondriopathy, including peripheral neuropathy, pancreatitis, hepatic steatosis, and lactic acidosis. 19 Table. Results from Randomized Trials Evaluating PEG-IFN α plus RBV with Standard IFN α plus RBV for Treating Patients Coinfected with HIV/HCV Treatment End-of-Treatment Sustained Virologic Discontinuation Response Response (adverse events; (PEG-IFN α plus (PEG-IFN α plus PEG-IFN α plus Treatment PEG-IFN α RBV RBV vs IFN α RBV vs RBV vs IFN α Study Patients, n Duration Regimen Regimen plus RBV) IFN α plus RBV) plus RBV) Laguno wk for geno N/A 44% vs 21% 12% vs 17% et al 10 types 1 and 4; mg/day mg/day (intent to treat; (P =.565) 24 wk for geno- P =.017) types 2 and 3 Chung wk for all 600 mg/day 600 mg/day 41% vs 12% 27% vs 12% 12% in both et al 11 genotypes escalated to escalated to (P <.001) (P =.03) groups 1000 mg/day 1000 mg/day Carrat wk for all 800 mg/day 800 mg/day 35% vs 21% 27% vs 20% 17% vs 16% et al 12 genotypes (P =.001) (P =.047) (P =.70) Torriani wk for all 800 mg/day 800 mg/day 47% vs 14% 40% vs 12% 12% vs 14% et al 13 genotypes N/A (P <.001) (P <.001) HCV = hepatitis C virus; HIV = human immunodeficiency virus; IFN α = interferon α; N/A = data not available; PEG-IFN α = pegylated interferon α; RBV = ribavirin. Advanced Studies in Medicine S367
3 CLINICAL EXPERIENCE WITH PEG-IFN α PLUS RBV IN HIV/HCV COINFECTION EFFICACY Recently, several large randomized clinical trials comparing PEG-IFN α plus RBV with IFN α plus RBV in patients coinfected with HIV/HCV have been completed (Table) The ACTG A5071 study compared the safety and efficacy of PEG-IFN α-2a at 180 µg/week with IFN α-2a at 6 MIU 3 times weekly for 12 weeks followed by 3 MIU 3 times weekly for 36 weeks, each combined with RBV on a dose-escalation schedule (600 mg/day for 4 weeks, 800 mg/day for 4 weeks, and then 1000 mg/day for the remainder of the study). Liver biopsy was performed in patients who had no virologic response (serum HCV RNA, 60 IU/mL) after 24 weeks of therapy, and only histologic responders (experiencing a 2 point improvement in hepatic activity index) were permitted to continue therapy to 48 weeks. Virologic responders at 24 weeks were allowed to complete the course of therapy, and biopsy was performed in these subjects at 48 weeks. The rate of end-of-treatment virologic response was higher in the group receiving PEG-IFN α-2a plus RBV compared to the group receiving IFN α-2a plus RBV (41% vs 12%; P <.001; Table). 11 Treatment with PEG-IFN α-2a plus RBV was also associated with a significantly higher SVR rate than the IFN α-2a plus RBV treatment (27% vs 12%; P =.03; Table). 11 As in studies of HCV monoinfection, patients with HCV genotypes other than genotype 1 had significantly higher rates of response to PEG-IFN α-2a compared to patients with genotype 1 (Figure 1). 11 For patients with genotype 1 infection, the rate of SVR was only 14% in the group receiving PEG-IFN α-2a plus RBV and 6% in the group receiving IFN α-2a plus RBV, whereas for those patients infected with other HCV genotypes (mainly genotypes 2 and 3), the respective rates of SVR were 73% and 33% (P <.001 compared to genotype 1 infections). 11 Among week-24 virologic nonresponders who underwent liver biopsy, histologic response was observed in 35% of patients, despite the absence of a significant decrease in HCV viremia. Among virologic responders at 24 weeks, 52% of patients experienced histologic improvement at week Lack of an early virologic response (clearance or 2 log 10 reduction of HCV RNA from baseline) at week 12 was uniformly predictive of failure to achieve an SVR (negative predictive value, 100%; Figure 2). 11 Two randomized studies, RIBAVIC and the study by Laguno et al, evaluated the use of PEG-IFN α-2b plus RBV in patients coinfected with HIV/HCV. 10,12 In 412 coinfected patients, the RIBAVIC trial (sponsored by the French National Research Group) compared PEG-IFN α-2b at 1.5 µg/kg/week with IFN α-2b at 3 MIU 3 times weekly; each was combined with a flat dose of RBV 800 mg/day (Table). 12 As in the ACTG A5071 trial, end-of-treatment responses and SVR rates were significantly higher for PEG-IFN α-2b plus RBV compared to IFN α-2b plus RBV. The SVR rate was 27% for PEG-IFN α-2b plus RBV compared to 20% for IFN α-2b plus RBV (P =.047). 12 The negative predictive value of virologic response at week 12 for SVR was 87%. In a smaller study, Laguno et al evaluated the efficacy and safety of IFN α-2b plus RBV with that of PEG-IFN α-2b plus RBV in 95 previously untreated patients with HCV coinfected with HIV. 10 Patients Figure 1. End-of-Treatment Response and SVR in Patients Coinfected with HIV/HCV Randomized to Receive PEG- IFN α-2a plus RBV or IFN α-2a plus RBV SVR, % * PEG-IFN α-2a/rbv All Genotype 1 Genotype non-1 IFN α-2a/rbv *P =.03 compared with IFN α-2a plus RBV. P <.01 compared with genotype 1. HCV = hepatitis C virus; HIV = human immunodeficiency virus; IFN α-2a = interferon α-2a; PEG-IFN α-2a = pegylated interferon α-2a; RBV = ribavirin; SVR = sustained virologic response. Data from Chung et al. 11 S368 Vol. 5 (4C) April 2005
4 were randomly assigned to treatment with IFN α-2b (3 MIU 3 times weekly) or PEG-IFN α-2b ( µg once weekly, adjusted to body weight) plus RBV ( mg/day, adjusted to body weight). In this study, an SVR at 48 weeks was observed in 44% of patients in the group receiving PEG-IFN α-2b plus RBV compared to only 21% of those patients in the group receiving IFN α-2b plus RBV (P =.017; Table). 10 Patients infected with HCV genotype 1 had higher response rates with PEG-IFN α-2b plus RBV compared to IFN α-2b plus RBV (38% vs 7%; P =.007). Sustained virologic response rates in patients with HCV genotypes 2 and 3 were 53% and 47% with PEG-IFN α-2b plus RBV and IFN α-2b plus RBV, respectively (P =.730). 10 TOLERABILITY Prior reports of HIV/HCV treatment with IFNα based regimens demonstrated high rates of patient dropout, often (although not exclusively) attributed to adverse event-related drug intolerance. In the ACTG A5071 trial, the combination of PEG-IFN α-2a plus RBV was well tolerated in patients coinfected with HIV/HCV. The discontinuation rate (12%) was similar in both treatment groups and was comparable to discontinuation rates reported in monoinfected patients with HCV in registration trials of PEG-IFN α-2a plus RBV. 6-8 These findings agree with those reported by Laguno et al for PEG-IFN α-2b plus RBV. 10 In contrast, a much higher rate of discontinuation and severe adverse events was reported in the RIBAVIC trial, in which 39% of patients discontinued treatment, 17% of patients because of severe adverse events. 12 The primary serious adverse events were development of mitochondrial injury leading to liver failure, lactic acidosis, or pancreatitis. Mitochondrial toxicity occurred most frequently in patients being treated with ddi before and during RBV treatment (odds ratio for ddi, 45%; 95% confidence interval = 7.2-infinity). 12 In ACTG A5071, a significant decrease in CD4+ cell count was noted by 24 weeks of therapy. 11 However, a slight increase in percentage of CD4+ cells was observed from baseline to week 24 (+3.5% for PEG- IFN α-2a plus RBV vs +2.5% for IFN α-2a plus RBV; P =.14). 11 No significant decrease in CD4+ cell count was noted in subsequent weeks of treatment. At the end of follow-up, a return to baseline levels was noted. HIV-1 RNA levels did not change appreciably during the study, and no clinical progression of HIV to AIDS was observed during the study period. 11 A similar effect on CD4+ cell counts was observed with PEG-IFN α- 2b plus RBV. 10 CONCLUSIONS Data from several large randomized studies clearly demonstrate that the combination of PEG-IFN α and RBV provides superior efficacy in achieving an SVR compared to the combination of standard IFN α and RBV. As with HCV monoinfection, significantly high- Figure 2. Predictive Value of an Early Virologic Response 106 subjects evaluated for early virologic response at wk had a decrease in HCV-RNA levels by 2 log IU/mL or to undetectable levels (41%) 63 did not have a decrease in HCV-RNA levels by 2 log IU/mL or to undetectable levels (59%) 63 did not have an SVR (100%) HCV = hepatitis C virus; SVR = sustained virologic response. Reprinted with permission from Chung et al. N Engl J Med. 2004;351: Copyright 2004, Massachusetts Medical Society. All rights reserved. 22 had an SVR (51%) 21 did not have an SVR (49%) 0 had an SVR Advanced Studies in Medicine S369
5 er response rates were achieved in patients with genotypes 2 and 3. Although PEG-IFN α plus RBV was well tolerated in the ACTG A5071 trial, higher rates of discontinuation because of serious adverse events were reported in the RIBAVIC trial. 12 These results suggest that dose escalation of RBV may play a role in enhancing drug tolerability. However, this may need to be weighed against reductions in SVR rate. To date, no anti-hcv agents have received approval for treatment of chronic HCV in patients coinfected with HIV. Therefore, the management of chronic HCV in patients coinfected with HIV has been based on clinical experience with HCV monoinfection. Evidence from the completed randomized studies support the use of PEG-IFN α plus RBV as the standard of care for treating chronic HCV in patients infected with HIV. However, several factors, including HCV genotype, extent of liver disease, and exposure to HAART, should be taken into account when considering a patient for PEG-IFN α plus RBV therapy. Evidence of histologic improvement, despite the absence of a significant decrease in HCV viremia observed in the ACTG A5071 trial, suggests that IFN-α based therapy may provide benefits independent of its antiviral effects and supports the need for investigation of maintenance strategies, especially in patients coinfected with HIV/HCV who have moderate-to-advanced fibrosis. Use of early predictors of virologic futility in patients infected with HIV receiving PEG-IFN α plus RBV may also allow the earlier termination of a medication that will not provide benefit while frequently being associated with adverse events. Based on the striking findings of the RIBAVIC study, patients should be switched from ddi-containing regimens before initiating combination therapy for HCV to avoid potentially harmful interactions between RBV and ddi. REFERENCES 1. Bräu N. Update on chronic hepatitis C in HIV/HCV-coinfected patients: viral interactions and therapy. AIDS. 2003;17: Soriano V, Sulkowski M, Bergin C, et al. Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV-HCV International Panel. AIDS. 2002; 16: Sherman KE. Diagnosis and management of the HCV/HIVcoinfected patient. AIDS Clin Care. 2002;14:39-43, Soriano V, Puoti M, Sulkowski M, et al. Care of patients with hepatitis C and HIV co-infection. AIDS. 2004;18: National Institutes of Health Consensus Development Conference Statement: management of hepatitis C: 2002 June 10-12, Hepatology. 2002;36(suppl 1):S3-S Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358: Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347: Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon alfa-2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140: Perez-Olmeda M, Nunez M, Romero M, et al. Pegylated IFN alpha-2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients. AIDS. 2003;17: Laguno M, Murillas J, Blanco JL, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients. AIDS. 2004;18:F27-F Chung RT, Andersen J, Volberding P, et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med. 2004;351: Carrat F, Bani-Sadr F, Pol S, et al. Pegylated interferon alfa- 2b vs standard interferon alfa-2b plus ribavirin for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA. 2004;292: Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med. 2004;351: Soriano V, Garcia-Samaniego J, Bravo R, et al. Interferon alpha for the treatment of chronic hepatitis C in patients infected with human immunodeficiency virus. Clin Infect Dis. 1996;23: Soriano V, Garcia-Samaniego J, Bravo R, et al. Relapses of chronic hepatitis C in HIV-infected patients who responded to interferon therapy. AIDS. 1997;11: Qurishi N, Kreuzberg C, Luchters G, et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet. 2003; 362: Poles M, Dieterich D. Hepatitis C virus/human immunodeficiency virus coinfection: clinical management of issues. Clin Infect Dis. 2000;31: Baba M, Pauwels R, Balzarini J, et al. Ribavirin antagonizes inhibitory effects of pyrimidine 2, 3 -dideoxynucleosides but enhances inhibitory effects of purine 2, 3 - dideoxynucleosides on replication of human immunodeficiency virus in vitro. Antimicrob Agents Chemother. 1987; 31: Lafeuillade A, Hittinger G, Chadapaud S. Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection. Lancet. 2001;357: S370 Vol. 5 (4C) April 2005
The medical management of hepatitis C
CLINICAL EXPERIENCE WITH PEGYLATED INTERFERON α-2a PLUS RIBAVIRIN FOR CHRONIC HEPATITIS C VIRUS INFECTION IN PATIENTS INFECTED WITH HIV: THE APRICOT STUDY Douglas T. Dieterich, MD* ABSTRACT Currently,
More informationTreatment Options in HCV Relapsers and Nonresponders. Raymond T. Chung, M.D.
Session IV Treatment Options in HCV Relapsers and Nonresponders Raymond T. Chung, M.D. Director of Hepatology, Massachusetts General Hospital, Associate Professor of Medicine, Harvard Medical School, Boston,
More informationAnemia in the Treatment of Hepatitis C Virus Infection
SUPPLEMENT ARTICLE Anemia in the Treatment of Hepatitis C Virus Infection Mark S. Sulkowski Center for Viral Hepatitis, Johns Hopkins University, Baltimore, Maryland Hepatitis C virus (HCV) infection is
More informationHIV and Hepatitis C Virus Coinfection: Bad Bedfellows
Perspective HIV and Hepatitis C Virus Coinfection: Bad Bedfellows Hepatitis C virus (HCV) infection is common in HIV-infected individuals and is responsible for increasing morbidity in these patients.
More informationPharmacological management of viruses in obese patients
Cubist Pharmaceuticals The Shape of Cures to Come Pharmacological management of viruses in obese patients Dr. Dimitar Tonev, Medical Director UKINORD 1 Disclosures } The author is a pharmaceutical physician
More informationةي : لآا ةرقبلا ةروس
سورة البقرة: اآلية HCV RELAPSERS AND NONRESPONDERS: How to deal with them? BY Prof. Mohamed Sharaf-Eldin Prof. of Hepatology and Gastroenterology Tanta University Achieving SVR The ability to achieve a
More informationSCIENTIFIC DISCUSSION
London, 26 April 2007 Product name: PegIntron Procedure No: EMEA/H/C/000280/II/0068 SCIENTIFIC DISCUSSION 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18
More informationCurrent therapy for hepatitis C: pegylated interferon and ribavirin
Clin Liver Dis 7 (2003) 149 161 Current therapy for hepatitis C: pegylated interferon and ribavirin John G. McHutchison, MD a, Michael W. Fried, MD b, * a Duke Clinical Research Institute, Duke University
More information29th Viral Hepatitis Prevention Board Meeting
29th Viral Hepatitis Prevention Board Meeting Madrid, November 2006 Treatment of chronic hepatitis C José M. Sánchez-Tapias Liver Unit Hospital Clínic University of Barcelona Spain CHRONIC HEPATITIS C
More informationLearning Objectives. Disclosures (Activity w/i 12 months) WHY DISCUSS HCV/HIV COINFECTION? HCV/HIV Effect on Health Utilization in A5001
Learning Objectives HCV/HIV COINFECTION Soup to Nuts Kenneth E. Sherman, MD, PhD Gould Professor of Medicine Director, Division of Digestive Diseases University of Cincinnati College of Medicine At the
More informationCase #1. Case #1. Case #1: Audience vote VS. The Great Debate: When to Treat HCV in our HIV coinfected patients
Case #1 The Great Debate: When to Treat HCV in our HIV coinfected patients Medical Management of AIDS December, 2012 Moderated by George Beatty,MD 35 year old African American man, CD4 + 450, HIV RNA
More informationTreatment algorithm for the management of hepatitis C in HIV-coinfected persons
Journal of Hepatology 44 (2006) S49 S55 www.elsevier.com/locate/jhep Treatment algorithm for the management of hepatitis C in HIV-coinfected persons Mark S. Sulkowski* Johns Hopkins Medical Institutions,
More informationManagement of CHC G1 patients who are relapsers or non-responders to Peg IFN and RBV therapy: Wait or Triple Therapy?
Management of CHC G1 patients who are relapsers or non-responders to Peg IFN and RBV therapy: Wait or Triple Therapy? Prof. Teerha Piratvisuth NKC Institute of Gastroenterology and Hepatology Prince of
More informationTreatment of HCV in HIV/HCV Coinfection: What Are the New Questions?
Treatment of HCV in HIV/HCV Coinfection: What Are the New Questions? Reprinted from The prn Notebook june 2005 Dr. James F. Braun, Editor-in-Chief Tim Horn, Executive Editor. Published in New York City
More informationOral combination therapy: future hepatitis C virus treatment? "Lancet Oct 30;376(9751): Oral combination therapy with a nucleoside
Author manuscript, published in "Journal of Hepatology 2011;55(4):933-5" DOI : 10.1016/j.jhep.2011.04.018 Oral combination therapy: future hepatitis C virus treatment? Commentary article on the following
More informationTreatment of HCV and HIV coinfection
Annals of Hepatology 2006; 5(Suppl. 1): S42-S48 Annals of Hepatology Treatment of HCV and HIV coinfection J. Alberto Juárez Navarro 1 Chronic infection with hepatitis C virus (HCV) affects 170 million
More informationHIV and Hepatitis C: Advances in Treatment
NORTHWEST AIDS EDUCATION AND TRAINING CENTER HIV and Hepatitis C: Advances in Treatment John Scott, MD, MSc Asst Professor University of Washington Presentation prepared & presented by: John Scott, MD,
More informationTreatment of acute hepatitis C infection in HIV-infected patients: a retrospective analysis of eleven cases
Journal of Viral Hepatitis, 2005, 12, 207 211 doi:10.1111/j.1365-2893.2005.00580.x Treatment of acute hepatitis C infection in HIV-infected patients: a retrospective analysis of eleven cases M. Vogel,
More informationTreatment of Hepatitis C in HIV-Coinfected Patients. Vincent Soriano Department of Infectious Diseases Hospital Carlos III Madrid, Spain
Treatment of Hepatitis C in HIV-Coinfected Patients Vincent Soriano Department of Infectious Diseases Hospital Carlos III Madrid, Spain Estimated no. of persons infected with HIV and hepatitis viruses
More informationPegylated Interferon Alfa-2b (Peg-Intron) Plus Ribavirin (Rebetol)in the Treatment of Chronic Hepatitis C: A Local Experience
Pegylated Interferon Alfa-2b (Peg-Intron) Plus Ribavirin (Rebetol)in the Treatment of Chronic Hepatitis C: A Local Experience E L Seow, PH Robert Ding Island Hospital, Penang, Malaysia. Introduction Hepatitis
More informationHIV coinfection and HCC
HIV coinfection and HCC 3 rd APASL STC on HCC 21 st -23 rd Nov 2013 Cebu, Phillippines George KK Lau MBBS (HK), MRCP(UK), FHKCP, FHKAM (GI), MD(HK), FRCP (Edin, Lond) Consultant, Humanity and Health GI
More informationHepatitis C in HIV Patients: The Speeding Sidecar. Andrew Desruisseau, MD,MSCI Assistant Professor Meharry Medical College
Hepatitis C in HIV Patients: The Speeding Sidecar Andrew Desruisseau, MD,MSCI Assistant Professor Meharry Medical College Patient: Mr. DW 40 year old AAM admitted with fever, nonproductive cough and hypoxemia
More informationCurrent Standard of Care for Naïve HCV Patients (SVR)
Hepatitis C: Non-responders Nikunj Shah, MD Associate Professor of medicine University of Illinois Medical center 1 Current Standard of Care for Naïve HCV Patients (SVR) 1 8 8 6 53 45 4 6 52 46 4 2 2 Peg
More informationSafety of Treatment in Cirrhotics in the Era of New Antiviral Therapies for Hepatitis C Virus
Safety of Treatment in Cirrhotics in the Era of New Antiviral Therapies for Hepatitis C Virus JEFFREY NADELSON MD, ALAN EPSTEIN MD, THOMAS SEPE MD BOSTON UNIVERSITY SCHOOL OF MEDICINE ROGER WILLIAMS MEDICAL
More informationIntron A Hepatitis B. Intron A (interferon alfa-2b) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.01 Subject: Intron A Hepatitis B Page: 1 of 7 Last Review Date: November 30, 2018 Intron A Hepatitis
More informationReviews/Evaluations. Chronic Hepatitis C. Introduction and Epidemiology. Natural Course of HCV. Recommendations for Treatment
Reviews/Evaluations Chronic Hepatitis C Introduction and Epidemiology Hepatitis C virus (HCV) is one of the most common blood-borne infections and cause of chronic liver disease in the United States (1).
More informationReview Optimizing outcomes in patients with hepatitis C virus genotype 2 or 3
Review Optimizing outcomes in patients with hepatitis C virus genotype 2 or 3 Thomas Berg 1 * and Giampiero Carosi 2 Antiviral Therapy 13 Suppl 1:17 22 1 Charite Universitatsmedizin Berlin, Berlin, Germany
More informationPeginterferon Alfa-2a plus Ribavirin versus Interferon Alfa-2a plus Ribavirin for Chronic Hepatitis C in HIV-Coinfected Persons
original article Alfa-2a plus Ribavirin versus Alfa-2a plus Ribavirin for Chronic Hepatitis C in HIV-Coinfected Persons Raymond T. Chung, M.D., Janet Andersen, Sc.D., Paul Volberding, M.D., Gregory K.
More informationHepatitis C & HIV Coinfection and Brief Advances on Hepatitis B & HIV: The Evidence and New Proposals
Hepatitis C & HIV Coinfection and Brief Advances on Hepatitis B & HIV: The Evidence and New Proposals Douglas G. Fish, MD Albany Medical College April 3, 2009 Cali Colombia Objectives HCV Epidemiology
More informationPredictors of severe haematological toxicity secondary to pegylated interferon plus ribavirin treatment in HIV HCV-coinfected patients
Antiviral Therapy 12:1225 1235 Predictors of severe haematological toxicity secondary to pegylated interferon plus ribavirin treatment in HIV HCV-coinfected patients José A Mira 1, Luis F López-Cortés
More informationORIGINAL RESEARCH. Introduction
DOI: 10.1111/ j.1468-1293.2007.00535.x HIV Medicine (2008), 9, 82 88 ORIGINAL RESEARCH r 2008 British HIV Association European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment
More informationSECTION 1: OLYSIO with (PEGASYS) AND RIBAVIRIN SECTION 2: OLYSIO with (PEGINTRON) AND RIBAVIRIN RATIONALE FOR INCLUSION IN PA PROGRAM
SECTION 1: OLYSIO with (PEGASYS) AND RIBAVIRIN SECTION 2: OLYSIO with (PEGINTRON) AND RIBAVIRIN RATIONALE FOR INCLUSION IN PA PROGRAM SECTION 1: OLYSIO with (PEGASYS) AND RIBAVIRIN Background Hepatitis
More informationScottish Medicines Consortium
Scottish Medicines Consortium pegylated interferon α 2b (ViraferonPeg ), 50, 80, 100, 120 or 150 micrograms powder for solution for injection in pre-filled pen, in combination with ribavirin (Rebetol ),
More informationManagement of HIV/HCV Coinfection: An Update
Management of HIV/HCV Coinfection: An Update Reprinted from The prn Notebook march 2004 Dr. James F. Braun, Editor-in-Chief Tim Horn, Executive Editor. Published in New York City by the Physicians Research
More informationPrediction of sustained virological response by ribavirin plasma concentration at week 4 of therapy in hepatitis C virus genotype 1 patients
Short communication Antiviral Therapy 13:607 611 Prediction of sustained virological response by ribavirin plasma concentration at week 4 of therapy in hepatitis C virus genotype 1 patients Marianne Maynard
More informationSimeprevir + PEG + RBV in Treatment-Naïve Genotype 1 QUEST-1 Trial
Phase 3 Treatment Naïve Simeprevir + in Treatment-Naïve Genotype 1 QUEST-1 Trial Jacobson IM, et al. Lancet. 2014;384:403-13. Simeprevir + PEG + Ribavirin for Treatment-Naïve HCV GT1 QUEST-1 Trial QUEST-1
More informationTherapy of Hepatitis C. Adrian M. Di Bisceglie
Session V Therapy of Hepatitis C Adrian M. Di Bisceglie Saint Louis University Liver Center, St. Louis, Mo. Tremendous progress has been made in developing effective therapies for hepatitis C. The process
More informationShould Elderly CHC Patients (>70 years old) be Treated?
Should Elderly CHC Patients (>70 years old) be Treated? Deepak Amarapurkar Consultant Gastroenterologist & Hepatologist Bombay Hospital & Medical Research Center, Mumbai & Jagjivanram Western Railway Hospital,
More informationSpecial Contribution Highlights of the 2012 American Association for the Study of Liver Diseases Meeting
Special Contribution Highlights of the 20 American Association for the Study of Liver Diseases Meeting Melissa K. Osborn, MD The American Association for the Study of Liver Diseases (AASLD) held its annual
More informationClinical cases: HIV/HCV coinfection
Clinical cases: HIV/HCV coinfection José Vicente Fernández-Montero Hospital Carlos III, Madrid Case #1 General considerations about antiviral therapy CASE # 1 43 year-old, male patient Former IDU No prior
More informationThe treatment of choice for chronic hepatitis C is
Early Identification of HCV Genotype 1 Patients Responding to 24 Weeks Peginterferon -2a (40 kd)/ribavirin Therapy Donald M. Jensen, 1 Timothy R. Morgan, 2 Patrick Marcellin, 3 Paul J. Pockros, 4 K. Rajender
More informationHepatitis C: Management of Previous Non-responders with First Line Protease Inhibitors
Hepatitis C: Management of Previous Non-responders with First Line Protease Inhibitors Fred Poordad, MD The Texas Liver Institute Clinical Professor of Medicine University of Texas Health Science Center
More informationOptimal Dosing Frequency of Pegylated Interferon Alfa-2b Monotherapy for Chronic Hepatitis C Virus Infection
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2005;3:610 615 Optimal Dosing Frequency of Pegylated Interferon Alfa-2b Monotherapy for Chronic Hepatitis C Virus Infection YOAV LURIE,* REGINE ROUZIER PANIS, GEORGE
More informationPegasys Ribavirin
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.08 Subsection: Anti-infective Agents Original Policy Date: January 1, 2006 Subject: Pegasys Ribavirin
More informationTreatment of Chronic Hepatitis C in HIV infection
Treatment of Chronic Hepatitis C in HIV infection June 25, 211 Andrew Talal, MD, MPH Associate Professor of Medicine Associate Medical Director Center for the Study of Hepatitis C Weill Cornell Medical
More informationDr. Siddharth Srivastava
Dr. Siddharth Srivastava MD, DM (Gastroenterology) Associate Professor GIPMER, New Delhi Rashtriya Gaurav Award 2013 for work on hepatitis B and C Set up Liver clinic at GIPMER and in charge EUS laboratory.
More informationPRACTICE GUIDELINES INTRODUCTION
American Journal of Gastroenterology ISSN 0002-9270 C 2006 by Am. Coll. of Gastroenterology doi: 10.1111/j.1572-0241.2006.00754.x Published by Blackwell Publishing PRACTICE GUIDELINES Management and Treatment
More informationPEARL-I. Ombitasvir + Paritaprevir + Ritonavir +/- Ribavirin in HCV GT4. Treatment Naïve and Treatment Experienced
Phase 2b Treatment Naïve and Treatment Experienced Ombitasvir + Paritaprevir + Ritonavir +/- Ribavirin in HCV GT4 PEARL-I Hézode C, et al. Lancet. 2015 March 30. [Epub ahead of print] PEARL-I: Study Design
More informationPhase 3. Treatment Experienced. Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2. Afdhal N, et al. N Engl J Med. 2014;370:
Phase 3 Treatment Experienced Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2 Afdhal N, et al. N Engl J Med. 2014;370:1483-93. Ledipasvir-Sofosbuvir +/- Ribavirin in Treatment-Experienced HCV
More informationAssessment of the Efficacy of Reducing Peginterferon Alfa-2a and Ribavirin Dose on Virologic Response in Koreans with Chronic Hepatitis C
ORIGINAL ARTICLE DOI: 10.3904/kjim.2009.24.3.203 Assessment of the Efficacy of Reducing Peginterferon Alfa-2a and Ribavirin Dose on Virologic Response in Koreans with Chronic Hepatitis C Jung Hyun Kwon
More informationTRANSPARENCY COMMITTEE
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 10 December 2008 REBETOL 200 mg capsules Pack of 84 (CIP code: 351 971.9) Pack of 112 (CIP code: 373 277.8) Pack of
More informationTreatment of chronic hepatitis C in HIV co-infected patients
Treatment of chronic hepatitis C in HIV co-infected patients Vicente Soriano Department of Infectious Diseases Hospital Carlos III, Madrid, Spain The most prevalent chronic viral infections in humans HBV
More informationClinicalTrials.gov Protocol Registration and Results System (PRS) Receipt Release Date: June 25, ClinicalTrials.gov ID: NCT
ClinicalTrials.gov Protocol Registration and Results System (PRS) Receipt Release Date: June 25, 2014 ClinicalTrials.gov ID: NCT00372385 Study Identification Unique Protocol ID: VX05-950-104EU Brief Title:
More informationDeterminants of Response to Pegylated Interferon and Ribavirin for Acute Hepatitis C Infection in Patients with Human Immunodeficiency Virus
Determinants of Response to Pegylated Interferon and Ribavirin for Acute Hepatitis C Infection in Patients with Human Immunodeficiency Virus Leah Burke, M.D. 1, Daniel Fierer, M.D. 2, David Cassagnol,
More informationIntravenous drug use is currently the main transmission
A Prospective Controlled Study of Interferon-Based Therapy of Chronic Hepatitis C in Patients on Methadone Maintenance Stefan Mauss, 1 Florian Berger, 1 Joerg Goelz, 2 Bernhard Jacob, 3 and Günther Schmutz
More informationInfergen (interferon alfacon-1) with Ribavirin (Copegus, Rebetol, RibaPak, Ribasphere, RibaTab, ribavirin tablets/capsules - all strengths)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.03.04 Subject: Infergen with Ribavirin Page: 1 of 8 Last Review Date: March 13, 2014 Infergen with Ribavirin
More informationAntiviral Therapy 13:
Antiviral Therapy 13:1047 1055 Original article Differences in virological response to pegylated interferon and ribavirin between hepatitis C virus (HCV)-monoinfected and HCV HIV-coinfected patients Cristina
More informationExpress Scripts, Inc. monograph dated 5/25/2011; selected revision 6/1/2011
BENEFIT DESCRIPTION AND LIMITATIONS OF COVERAGE ITEM: PRODUCT LINES: COVERED UNDER: DESCRIPTION: CPT/HCPCS Code: Company Supplying: Setting: Coverage Criteria: Approval Period: Victrelis (boceprevir capsules)
More informationThe role of triple therapy with protease inhibitors in hepatitis C virus genotype 1na «ve patients
The role of triple therapy with protease inhibitors in hepatitis C virus genotype 1na «ve patients David R. Nelson Clinical and Translational Science Institute, University of Florida, FL, USA Liver International
More informationHepatitis C Therapy Falk Symposium September 20, 2008
Hepatitis C Therapy Falk Symposium September 20, 2008 Ira M. Jacobson, MD Vincent Astor Professor of Clinical Medicine Chief, Division of Gastroenterology and Hepatology Medical Director, Center for the
More informationImproving Treatment Success Rates for HCV in a Managed Care Setting
Improving Treatment Success Rates for HCV in a Managed Care Setting Bruce R. Bacon, MD James F. King MD Endowed Chair in Gastroenterology Professor of Internal Medicine Division of Gastroenterology and
More informationTreatment of HCV in Persons with HIV Coinfection
Hepatitis C Online PDF created October 2, 2018, 12:45 pm Treatment of HCV in Persons with HIV Coinfection This is a PDF version of the following document: Section 6: Treatment of Key Populations and Unique
More informationHepatitis C Management and Treatment
Hepatitis C Management and Treatment Kaya Süer Near East University Faculty of Medicine Infectious Diseases and Clinical Microbiology 1 Discovery of Hepatitis C Key facts Hepatitis C: the virus can cause
More informationRibavirin (Medicare Prior Authorization)
Prior Authorization Form ARKANSAS BLUE CROSS AND BLUE SHIELD Medi-Pak Rx (PDP), Medi-Pak Advantage (PFFS), and Medi-Pak Advantage PPO Ribavirin (Medicare Prior Authorization) This fax machine is located
More informationTreatment Initiation and Monitoring in HIV/HCV Co-infected Patients
Treatment Initiation and Monitoring in HIV/HCV Co-infected Patients Todd S. Wills, MD University of South Florida Hepatitis C Treatment Expansion Initiative Evaluation and Technical Assistance Center HCV
More informationViral hepatitis and HIV coinfection q
Journal of Hepatology 48 (2008) 353 367 Review Viral hepatitis and HIV coinfection q www.elsevier.com/locate/jhep Mark S. Sulkowski * Johns Hopkins University School of Medicine, 600 rth Wolfe Street,
More informationGlobal Hepatitis Programme. Guideline development for Hepatitis C virus Screening, Care and Treatment in low- and middle-income countries
WHO/HIV/2014.26 World Health Organization 2014 Global Hepatitis Programme Guideline development for Hepatitis C virus Screening, Care and Treatment in low- and middle-income countries WHO TECHNICAL REPORT
More information5/12/2016. Learning Objectives. Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients
5/12/216 Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients Alexander Monto, MD Professor of Clinical Medicine University of California San Francisco San Francisco,
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 14 December 2011
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 14 December 2011 INCIVO 375 mg, film-coated tablet B/4 bottles of 42 tablets (CIP code: 217 378-5) B/1 bottle of 42
More information47 th Annual Meeting AISF
47 th Annual Meeting AISF Rome, 21 February 2014 Present and future treatment strategies for patients with HCV infection: chronic hepatitis and special populations (HCV/HIV coinfection, advanced cirrhosis,
More informationTRANSPARENCY COMMITTEE OPINION. 10 December 2008
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 10 December 2008 VIRAFERONPEG 50 µg/ 0.5 ml powder and solvent for injectable solution Pack of 1 (CIP: 355 189.3)
More informationHEPATITIS C TREATMENT GUIDANCE
HEPATITIS C TREATMENT GUIDANCE These guidelines have been produced based on the NICE Guidance TA200 Peginterferon alfa and ribavirin for the treatment of chronic hepatitis c and the summaries of product
More informationClinical Criteria for Hepatitis C (HCV) Therapy
Diagnosis Clinical Criteria for Hepatitis C (HCV) Therapy Must have chronic hepatitis C (HCV infection > 6 months), genotype and sub-genotype specified to determine the length of therapy; Liver biopsy
More informationNew developments in HCV research and their implications for front-line practice
New developments in HCV research and their implications for front-line practice Dr. Curtis Cooper Associate Professor, University of Ottawa Director, Ottawa Hospital Viral Hepatitis Program June 17, 2013
More informationGenerally, any patient with virologic or histologic signs
REPORTS Into the Light: Strategies for Battling Hepatitis C Bruce R. Bacon, MD; and John G. McHutchison, MD Generally, any patient with virologic or histologic signs of chronic hepatitis C virus (HCV)
More informationTreatment of Chronic Hepatitis C in Non-Responders
Management of Patients with Viral Hepatitis, Paris, 2004 Treatment of Chronic Hepatitis C in Non-Responders Jay H. Hoofnagle INTRODUCTION The treatment of chronic hepatitis C has evolved markedly over
More informationCHRONIC HCV TREATMENT: In Special Populations.
CHRONIC HCV TREATMENT: In Special Populations. By Taher EL-ZANATY Prof. of Internal Medicine CAIRO UNIVERSITY Introduction: HCV is the major cause of chronic hepatitis in Egypt. Its end stage is liver
More informationTopic: Sovaldi, sofosbuvir Date of Origin: March 14, Committee Approval Date: August 15, 2014 Next Review Date: March 2015
Medication Policy Manual Policy No: dru332 Topic: Sovaldi, sofosbuvir Date of Origin: March 14, 2014 Committee Approval Date: August 15, 2014 Next Review Date: March 2015 Effective Date: October 1, 2014
More informationNew Therapies on the Horizon in Hepatitis C Patients Paul Y. Kwo, MD
Viral Targets for HCV New Therapies on the Horizon in Hepatitis C Patients Paul Y. Kwo, MD Sites for development of inhibitors Metalloproteinase Serine protease (trans) Core E E2 NS2 NS3 NS4a/NS4b NS5a/NS5b
More informationRibavirin (Copegus, Ibavyr, Moderiba)
FACTSHEET Ribavirin (Copegus, Ibavyr, Moderiba) Summary Ribavirin is a medication used to treat hepatitis C. It is used in combination with other medications to cure people of the hepatitis C virus. Ribavirin
More informationTratamiento de la Hepatitis C Rafael Esteban Hospital General Universitario Valle de Hebrón Barcelona
Tratamiento de la Hepatitis C Rafael Esteban Hospital General Universitario Valle de Hebrón Barcelona rrent HCV Therapy 8% % sustained response 6% 4% 2% % 54-61% 41% 34% 25% 16% 6% IFN 24w IFN 48w Peg
More informationCASE STUDY. Adverse Events in treatment chronic hepatitis C patients with PegInterferon and Ribavirin What would your management decision be?
Adverse Events in treatment chronic hepatitis C patients with PegInterferon and Ribavirin What would your management decision be? CASE STUDY Pham Thi Thu Thuy MD, PhD Ho Chi Minh City Vietnam Serious Adverse
More informationSpecifically Targeted Antiviral Therapy (STAT-C) for Patients With Chronic Hepatitis C
Specifically Targeted Antiviral Therapy (STAT-C) for Patients With Chronic Hepatitis C Zobair M. Younossi, MD, MPH, FACP, FACG Medscape Gastroenterology. 2007; 2007 Medscape Posted 06/01/2007 Introduction
More informationOriginal article OPERA: use of pegylated interferon plus ribavirin for treating HCV HIV coinfection in interferon naive patients
Antiviral Therapy 14; 19:735 745 (doi:.3851/imp2757) Original article OPERA: use of pegylated interferon plus ribavirin for treating HCV HIV coinfection in interferon naive patients Giampiero Carosi 1,
More informationHow to optimize current therapy for GT1 patients Shortened therapy with IFNa-based therapy
How to optimize current therapy for GT1 patients Shortened therapy with IFNa-based therapy Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber- und Studienzentrum
More informationThe decision to treat hepatitis C virus. Managing Hepatitis C REPORTS. Bruce R. Bacon, MD
Bruce R. Bacon, MD Abstract Availability of a drug regimen that eradicates the hepatitis C virus (HCV) in more than half of treated patients provides the medical community with a powerful new weapon to
More informationPharmacodynamics of PEG-IFN alpha-2a and HCV response as a function of IL28B polymorphism in HIV/HCV co-infected patients
1 Pharmacodynamics of PEG-IFN alpha-2a and HCV response as a function of IL28B polymorphism in HIV/HCV co-infected patients Evaldo Stanislau Affonso de Araújo 1*&, Harel Dahari 2*$, Scott J Cotler 2, Thomas
More informationViral hepatitis in reproductive health. Pierre Jean Malè. Training in Reproductive Health Research - Geneva 2006
Viral hepatitis in reproductive health Pierre Jean Malè Training in Reproductive Health Research - Geneva 2006 15.03.2006 HBV and HCV treatment Pierre-Jean Malè MD 15.03.2006 Global Impact of Hepatitis
More informationV. Hepatitis C Treatment
V. Hepatitis C Treatment Summary The current standard of treatment for hepatitis C virus (HCV) is a combination of two drugs: pegylated interferon and ribavirin. The virological response rate, treatment
More informationDirect acting anti-virals: the near future
Direct acting anti-virals: the near future Heiner Wedemeyer Hannover Medical School Germany Will IFN-free treatment be possible in the near future? Interferon-free regimens to treat hepatitis C What should
More informationOlysio PegIntron Ribavirin
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.27 Subject: Olysio PegIntron Ribavirin Page: 1 of 7 Last Review Date: March 18, 2016 Olysio PegIntron
More informationHepatitis C Treatment
Hepatitis C Treatment Standard of care & Managing advrse events Mohssen Nassiri Toosi, MD A s s o c i a t e P ro f e s s o r Of Internal M e d i c i n e Te h r a n U n i v e r s i t y O f M e d i c a l
More informationOlysio Pegasys Ribavirin
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.28 Subject: Olysio Pegasys Ribavirin Page: 1 of 7 Last Review Date: March 18, 2016 Olysio Pegasys
More informationPegasys Pegintron Ribavirin
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.47 Subsection: Anti-infective nts Original Policy Date: January 1, 2019 Subject: Pegasys Pegintron
More informationProspective Analysis of Patient Education Time and Administration Errors Associated with Administration of Pegasys versus Peg-Intron
Prospective Analysis of Patient Education Time and Administration Errors Associated with Administration of Pegasys versus Peg-Intron David Finkelman, MD, MBA Janet McRea, LPN Reprint requests to: David
More informationThe time factor in the management of chronic hepatitis C
11-8/8//4/2-235 REVISTA ESPAÑOLA DE ENFERMEDADES DIGESTIVAS Copyright 8 ARÁN EDICIONES, S. L. REV ESP ENFERM DIG (Madrid) Vol.. N. 4, pp. 2-235, 8 POINT OF VIEW The time factor in the management of chronic
More informationStrategies for Managing Hepatitis C Virus Infection in HIV-Infected Patients
Perspective Strategies for Managing Hepatitis C Virus Infection in HIV-Infected Patients Challenges in the Management of HIV/HCV Coinfection Hepatitis C virus (HCV) infection is a common comorbidity in
More informationProvisional Guidance on the Use of Hepatitis C Virus Protease Inhibitors for Treatment of Hepatitis C in HIV-Infected Persons
INVITED ARTICLE HIV/AIDS Kenneth H. Mayer, Section Editor Provisional Guidance on the Use of Hepatitis C Virus Protease Inhibitors for Treatment of Hepatitis C in HIV-Infected Persons David L. Thomas,
More informationTreatment Outcome in Chronic Hepatitis C Infection: A Four Years Survey Among Iranian Patients
Global Journal of Health Science; Vol. 7, No. 3; 2015 ISSN 1916-9736 E-ISSN 1916-9744 Published by Canadian Center of Science and Education Treatment Outcome in Chronic Hepatitis C Infection: A Four Years
More informationManagement of chronic hepatitis C treatment failures: role of consensus interferon
REVIEW Management of chronic hepatitis C treatment failures: role of consensus interferon Stevan A Gonzalez 1 Emmet B Keeffe 2 1 Division of Hepatology, Baylor Regional Transplant Institute, Baylor All
More information